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Tuberculosis (TB) remains a major public health problem internationally, causing 9.6 million new cases
and 1.5 million deaths worldwide in 2014. The Bacillus Calmette-Guerin vaccine is the only licensed
vaccine against TB, but its protective effect does not extend to controlling the development of infectious
pulmonary disease in adults. The development of a more effective vaccine against TB is therefore a
pressing need for global health. Although it is established that cell-mediated immunity is necessary for
the control of latent infection, the presupposition that such immunity is sufﬁcient for vaccine-induced
protection has recently been challenged. A greater understanding of protective immunity against TB is
required to guide future vaccine strategies against TB.
In contrast to cell-mediated immunity, the human antibody response against M.tb is conventionally
thought to exert little immune control over the course of infection. Humoral responses are prominent
during active TB disease, and have even been postulated to contribute to immunopathology. However,
there is evidence to suggest that speciﬁc antibodies may limit the dissemination of M.tb, and potentially
also play a role in prevention of infection via mucosal immunity. Further, antibodies are now understood
to confer protection against a range of intracellular pathogens by modulating immunity via Fc-receptor
mediated phagocytosis. In this review, we will explore the evidence that antibody-mediated immunity
could be reconsidered in the search for new vaccine strategies against TB.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Tuberculosis (TB) is the leading cause of death from bacterial
infectionworldwide, with 9.6 million cases and 1.5 million deaths in
2014 [1]. The Bacillus CalmetteeGuerin (BCG) vaccine was intro-
duced to prevent disease during the mid-20th century but, despite
widespread coverage, has failed to control the spread of TB in high
burden areas [1]. The continuing rise of infections in such areas
despite vaccination is in part due to the BCG vaccine's variable ef-
ﬁcacy in preventing the development of adult pulmonary TB [2,3].
Expectoration of Mycobacterium tuberculosis (M.tb), the causative
agent of TB, by adults with active pulmonary disease drives the
ongoing transmission of the disease. There is an urgent need for a
more effective vaccine against TB, as theWHO Stop TB collaboration's
goal of eliminating TB as a threat to global health cannot be reached
even with optimal implementation of current interventions [4].
The existence of natural immunity against TB is supported by
the observation that nine out of ten individuals appear able to
control infection with M.tb in a state of clinical latency [5]. How-
ever, the precise immune requirements needed for this immunity
are incompletely deﬁned, and hence the immune response to target
by vaccination remains elusive [6]. The contribution of cell-
mediated immunity (CMI) here has been ﬁrmly established in
past decades, and it is thus reasonable that a vaccine against TB
should induce a CD4þ T-cell response against immunodominant T-
cell antigens [6]. The MVA85A is one such vaccine and was recently
tested in two landmark efﬁcacy trials [7,8]. Despite demonstrating
protection in some animal models, and inducing antigen speciﬁc
CD4þ T-cells, MVA85A was unable to add to the protection
assumed to be provided by BCG [7,8]. Many candidate vaccines
against TB target a similarly narrow immune repertoire, and thus
the disappointing outcome of the MVA85A trials has provided
impetus to explore a wider range of immune responses in protec-
tion against TB [9,10].
Antibody-mediated immunity (AMI) is one such approach. As
M.tb is a facultative intracellular pathogen, it has been postulated
that antibodies either have no protective beneﬁt or may even
contribute to immunopathology in active disease [11]. Surmount-
ing this presumed lack of functional antibodies in TB presents a
substantial challenge for the next generation of vaccines against TB,
as antibody titre and speciﬁcity remains the predominant correlate
of vaccine-induced immunity for many other diseases [12]. Even in
diseases where antibodies produced during infection fail to confer
protection, vaccines have been designed to induce antibodies
capable of protecting from disease. Such ‘synthetic’ or non-naturalimmunity utilizing antibodies may present a novel testable vaccine
hypothesis against TB. Herewewill explore the recent expansion of
evidence that a role for antibodies in immunity is worthy of
consideration in designing future vaccine strategies against TB.
1.1. Humoral immunity during natural infection with TB
1.1.1. Variation in human antibody responses against M.tb
It has long been known that natural infection induces the for-
mation of antibodies against M.tb. In the late 19th century it was
thought that antibodies formed in inoculated animals would be
able to treat infection in patients as this approach was successful in
pneumococcal disease [13]. The inconsistent trial results that fol-
lowed were an early clue to the complexity of the antibody
response against M.tb [13].
Studies following on from these original trials demonstrated
that 90% of TB patients have raised titres of serum immunoglobulin
against mycobacterial antigens at the time of clinical presentation
[14]. However, the antigens targeted by individual patients vary
widely, as one study showed that out of a panel of ten culture
ﬁltrate proteins secreted byM.tb, no single antigen was universally
recognized by serum from patients with active TB [14]. The corre-
lation between antibody responses and active TB disease led to
investigation of antibodies as diagnostic markers rather than a
therapeutic strategy, but these efforts were discouraged by the
WHO in 2012, due to suboptimal sensitivity and speciﬁcity in
studies [15]. It should be noted however that this recommendation
was only directed towards the diagnostic use of current commer-
cially available tests and not towards investigation into the function
of antibodies in immunity against TB as a whole. Many factors in-
ﬂuence the development of antibodies during the course of infec-
tion including latency, stage of infection, HIV and host genotype as
summarized in Table 1.
1.1.2. Markers of humoral immunity in recent studies
A consistent ﬁnding in whole blood transcription studies in
active TB, spanning geographical locations and in HIV-1 co-infec-
tion, is the up-regulation of the high-afﬁnity antibody receptor
FCgR1A [16e18]. Fcgr1A binds antibody principally of the IgG1 and
IgG3 subtype and is expressed mainly in macrophages and den-
dritic cells [19]. The expression of complement C1q, which forms
immune complexes with immunoglobulin, is also elevated during
active TB and is associated with increased disease severity [17,20].
Further analysis of transcription studies have shown TRIM21, a
recently identiﬁed intracellular antibody receptor, to also be
Table 1
Factors related to the development of antibodies against M.tb in humans.
Active disease Latent infection Effect of anti-TB
treatment
Bacterial factors HIV co-infection Host genetics
Hypergammaglobulinemia
in 90% of patients [14]
Range of antibodies
may reﬂect antigens
produced by M.tb
during latency e.g. Acr
[44]
Broader range of
antigens recognized
possibly due to
antigens presented
from killed bacilli [127]
Expression of antigens vary
in different strains of M.tb
and may inﬂuence humoral
responses [128]
Greater homogeneity in IgG
subclass recognizing LAM.
IgG1 and IgG4 produced
against LAM but not IgG2
[102]
Association with HLA-
DR15 to development
of active TB and higher
anti-38 kDa antibody
levels [129]
Raised mycobacteria-
speciﬁc plasmablasts and
plasma cell counts in
peripheral circulation
[130]
In high exposure
settings, high titres of
antibodies against CFP-
10 and ESAT-6 are
frequently seen in
latency [131]
Gradual decrease in
antibody titres as active
disease resolves [132]
Bacterial expression of
antigens during replication
and dormancy may
inﬂuence humoral
responses [132]
Recognition of certain
antigens such as MPT51
correlate stronger to active
TB disease in HIV-1 infected
persons than non-infected
individuals [133]
HLA-DR2 and HLA-
DQw1 associated with
recognition of the TB71
and TB72 epitopes of
the 38-kDa antigen
[129]
Sputum smear-positive
disease associated with
higher titres of
antibodies than other
forms of disease [129]
Prevalence of patients with
IgG against PPD decreases
with lower CD4þ counts
[39]
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nalling pathways known to be important in the control of adeno-
virus and salmonella infection by activation of NFkB and
proteasomal degradation pathways [22] What function TRIM21
may play in TB is however speculative at present [22].
Humoral immunity is also stimulated at the site of disease:
pulmonary TB is associated with an increase in the Th2 cytokines
IL-4, CCL-4 and SOCS3 in bronchoalveolar lavage (BAL) ﬂuid taken
from patients with active pulmonary TB [23]. IL-4 levels in sputum
correspond to increased bacterial load and antibody levels in serum
[24]. Antibodies are present in the sputum of patients with active
pulmonary TB as shown by mass spectroscopy [25]. This polariza-
tion towards a humoral immune response has previously been
hypothesized to represent immune evasion by the skewing of host
responses away from a protective Th1-mediated response [23].
Despite the variable AMI response in individual patients and the
association of antibody responses with the clinical state of active
disease, there are multiple clinical scenarios in which AMI may be
protective against M.tb.
1.2. Antibody-mediated protection in humans
1.2.1. Humoral immunodeﬁciency and risk of TB
Clinical observations have offered considerable insights into
understanding natural immunity to M.tb infection. Clear examples
of these ﬁndings include the observation that HIV-infected patients
are at greater risk of developing TB, and the loss of CD4þ cells
correlates to an increasing risk of disseminated disease [26]. Ge-
netic susceptibility tomycobacterial disease is well described and is
typically seen in loss of functionality in the IL-12, STAT1 and IFN-g
pathways [27]. If humoral immunity plays a role in mediating
protection against TB, we could reasonably expect to observe pa-
tients with attenuation of antibody responses to be at greater risk of
developing active infection.
1.2.1.1. Clinical observations suggesting little role for antibodies in TB
immunity. Meta-analysis in diseases leading to a loss of antibody
such as X-linked agammaglobulinemia or common variable im-
munodeﬁciency (CVID) have not shown an increased risk of active
TB, although these ﬁndings may be confounded by variable
exposure to M.tb and intravenous immunoglobulin (IVIG)
replacement [28]. In patients taking Rituximab, an anti-CD20
monoclonal antibody that depletes populations of naïve B-cells,
there does not appear to be an increased risk of TB reactivation
[29]. This is in contrast to patients taking anti-TNF-a monoclonalantibodies for rheumatic conditions who are at increased risk of
reactivation TB [30].
1.2.1.2. Clinical observations in favor of a role for antibodies in TB
immunity. Case reports of endobronchial tuberculosis in X-linked
agammaglobulinemia, cutaneous mycobacterial infection in selec-
tive IgA deﬁciency and extra-pulmonary TB in autosomal recessive
hyper-IgM syndrome have been reported [31e33]. Autosomal
recessive hyper-IgM syndrome prevents the hyper-mutation of
speciﬁc immunoglobulins, with intact cellular immunity, unlike X-
linked forms where T-cell activation is impaired [31e33]. Although
these appear in isolation, they do suggest a contributing role of
antibodies in immunity against mycobacterial infection.
1.2.2. Antibodies modulate severity of TB disease
An alternative role for antibodies could be to modulate the
course of M.tb infection. Disseminated TB has a higher mortality
rate than pulmonary TB, and the ﬁnding that children without
detectable antibodies against LAM, or to extracts of mycobacteria
rich in LAM, are at greater risk of disseminated TB is of note [34].
Corroborating this ﬁnding is that the period of greatest risk for
disseminated disease corresponds to a trough in antibody titres
against LAM between the ages of six months and three years [34].
A similar phenomenon was observed for antibodies against the
38 kDa antigen of M.tb [35]. A lack of antibodies against this
protein is associated with the development of extra-pulmonary
TB in children or TB meningitis in adults, and ELISA detecting
this antigen has been used to diagnose TB from CSF [35].
Furthermore, Ziegenbalg et al. screened patients for antibodies
against mycobacterial membrane vesicles containing an abun-
dance of surface proteins and glycolipids, and the three patients
in the cohort with disseminated disease lacked antibodies
against these antigens [36].
Recently, higher titres of IgG against Ag85A have been shown to
associate with reduced risk of developing active disease in an infant
case-control study [37]. This raises the possibility that anti-
mycobacterial antibodies assist in the containment of initial infec-
tion with M.tb in humans. The presence of IgG against Ag85A has
elsewhere been associated with decreased cavitation and a greater
chance of sputum clearance ofM.tb in a cohort of Mexican patients
[38] The development of clinically deﬁned AIDS is associated with
waning antibody titres against M.tb antigens in puriﬁed protein
derivative (PPD)e suggesting that the risk for severe disease in this
populationmay not be exclusively due to loss of CD4þ cells [39]. IgA
against aecrystallin (Acr) and HrpA are associated with improved
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albumin and CRP levels seen in patients with higher titres of anti-
bodies against these antigens [40]. These ﬁndings suggest that a
vaccine eliciting such antibodies may prevent extrapulmonary TB
and thus reduce mortality and morbidity from TB.
1.2.3. Antibodies in prevention of infection with M.tb
It has been conjectured that if protective antibodies in TB are
present in humans, that they may have a role in preventing the
initial acquisition of infection with M.tb [41]. The discovery of
individuals in high-exposure settings that do not have a detect-
able T-cell response to M.tb antigens by tuberculin skin testing
(TST) or ex vivo stimulation has triggered interest in the search for
individuals with unusually effective immune responses against TB
[42]. This phenotype was established with the ﬁnding that 20% of
individuals from a hyper-endemic area remain unreactive to TST,
without signs of infection, representing possible natural resis-
tance to infection [42]. Genome-wide linkage survey performed
on these patients revealed two loci potentially responsible for this
phenotype on chromosomes 11p14 and 5p15 linked to a TNF-a
response element [42]. A similar cohort of nurses in a TB ward that
remained TST-negative despite years of exposure underwent
antibody repertoire sequencing with next-generation sequencing
[43]. Here an IgA gene rearrangement of VH3-23-D3-3-J4 was
predominant amongst those nurses who remained TST-negative
and did not develop active disease compared to their TST reac-
tive colleagues [43]. An earlier study of nurses exposed to TB
revealed a strong antibody response against a non-
immunodominant epitope of Acr [44]. A possible conclusion of
such studies is that these individuals produce antibodies against
M.tb that prevent or help resolve infection despite high exposure
to the bacillus
Further suggestion for the role of antibodies in individuals with
a long duration of close contact to active TB patients that remain
TST-negative is that these individuals display increased levels of IgG
against M.tb, and that their serum is able to block or enhance
stimulation of autologous T-cells in PBMC by puriﬁed protein de-
rivative (PPD) [45]. Individuals highly exposed to TB produce high
levels of IgG against M.tb PPD, and antibody levels against myco-
bacterial surface polysaccharides in healthy individuals from India
were found to match those in patients with active disease [46,47].
Although these ﬁndings are suggestive of a role for antibodies in
protection, prospective studies would demonstrate if heightened
antibody responses associate with long-term reduction in risk for
developing active or latent TB [48]. If this is found to be the case, it
would strongly support existing studies that the induction of AMI
by vaccination offers a mechanism whereby the initial acquisition
of infection can be prevented.
1.3. The role of opsonizing antibodies and antibody isotypes against
M.tb
M.tb is one of the most successful human pathogens, owing to
millennia of coevolution, and as such, has an array of mechanisms
to circumvent the establishment of a protective immune response
[49]. The intracellular niche ofM.tb allows it to avoid antibodies for
parts of it lifecycle, but additional defences mechanisms against
AMI may be present and provide an explanation for why antibodies
do not appear to protect against active TB. If understood, these
mechanisms could potentially by circumvented by vaccination to
produce protective antibodies.
1.3.1. Sites of interaction between antibodies and M.tb
A major criticism against the role of antibodies in immunity
againstM.tb is the question of where antibodies could interact withsufﬁcient effect against the bacillus. Antibodies are present in both
the upper and lower lung ﬁelds e IgA predominates in the upper
airway and IgG in the lower airway [12]. Human infectionwithM.tb
does induce IgG and IgA formation against M.tb antigens in BAL
ﬂuid, although the extent of interaction between antibodies in the
respiratory mucosa and inhaled M.tb is essentially unknown
[50,51].
There is clear indication that antibodies are able to bind M.tb
antigens at the site of infection. B-cells surround the granuloma in
non-human primates and these cells display an activated
antibody-secreting phenotype [52]. The lung tissue and draining
lymph nodes of the rhesus macaques in this study were also
enriched for plasma cells and immunoglobulin against the M.tb
antigens CFP-10 and ESAT-6 [52]. In humans, activated M.tb-spe-
ciﬁc B-cells are found in the pleural ﬂuid in patients with pleural
TB [53]. Such antibody-secreting B-cells in the granuloma may
secrete immunoglobulin that interacts with extracellular bacilli.
M.tb is extracellular during reinfection of host cells as well as at the
time of expectoration, and the guinea pig model has also shown
that the necrotic core and acellular rim of the granuloma also
contains signiﬁcant numbers of extracellular bacilli [54]. Given the
robust signal of FcyR pathway activation in active TB tran-
scriptomic signatures, these antibodies could serve to bind free
M.tb antigens or the bacillus itself and beneﬁcially modulate
macrophage activation.
1.3.2. Surface binding antibodies against M.tb
Vaccines against bacterial pathogens typically induce antibodies
that are able to opsonize bacteria and initiate complement-
mediated lysis and uptake into neutrophils for destruction [12].
Even in intracellular bacterial infections such as S. typhi, surface-
binding antibodies are able to trigger killing by opsonophagocy-
tosis during the extracellular phase of their lifecycles [55]. M.tb
presents the substantial challenge of a lipid-rich cell membrane
and less potential exposure to antibodies via haematogenous
spread. However, in an experimental of model Cryptococcus neo-
formans, a fungal pathogen with a similar waxy capsule, antibodies
are able to bind surface-expressed antigens and provide protection
by altering fungal gene expression and increasing sensitivity to
antifungal drugs [56,57].
It is therefore notable that active tuberculosis seems to stimu-
late an antibody response predominantly against secreted antigens
rather than against surface-exposed antigens. Kunnath-
Velayudhana et al. compared serum binding to a TB protein
microarray which represented linearized copies of 1200 proteins,
allowing determination of the antigenic repertoire of M.tb in pa-
tients with active TB disease. The proteins recognized by these
individuals was restricted to 0.5% of theM.tb proteome, and greatly
enriched for secreted and cytosolic antigens in comparison to
healthy controls [58]. Antibodies binding these groups of antigens
would likely not be able to directly bind M.tb during any extracel-
lular periods.
More recent studies from other groups have since improved
on the expression systems to represent a broader range of pro-
teins, still demonstrating a narrow range of antigens targeted
during infection compared to the total proteome of M.tb [59,60].
Further, the development of active TB in humans is associated
with a drop in avidity of antibodies that are able to directly bind
the surface of live bacilli [61]. Antibodies against secreted pro-
teins and lysate preparations increase in avidity and titre in
comparison to controls, again demonstrating that M.tb strongly
induces humoral immunity but potentially not antibodies that are
able to opsonize it [61]. Vaccine induction of antibodies capable
of opsonizing M.tb may therefore be a potential approach to
harnessing AMI in TB.
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The existence of functional antibodies recognizing M.tb surface
antigens would be further supported by evidence for immune
evasion by antigenic variation in these targets. Immunodominant
T-cell epitopes of M.tb are postulated to be hyperconserved, sug-
gesting that recognition of these epitopes by host T-cells may favor
bacterial survival and transmission [62]. MPT64 is a known B-cell
surface and secreted antigen and polymorphisms in clinical isolates
predominately affected B-cell epitopes, with 85.71% of mutations
occurring in B-cell epitopes [63,64]. Mutations in this protein may
affect both its structure and surface expression [63,64]. The
PE_PGRS33 protein is also immunogenic and forms part of the PE/
PPE complex involved in pathogenesis, with 84 of 123 clinical iso-
lates showing sequence variation compared toM.tb H37Rv [65,66].
These ﬁndings lend further credence to the hypothesis that surface
antigens are under evolutionary pressure from the host immune
system and may be epitopes of functional antibodies in the human
host.
1.3.4. The role of antibody subclasses in protection
Antibody subclass may also be a factor in the apparent lack of
protection from antibodies during natural TB infection, as sub-
classes have variable roles in facilitating interaction with other
immune cells [67]. IgG1 and IgG3 are the predominant human
antibody subclasses formed against TB [68]. IgG1, but not IgG3,
from TB patients is able to stimulate release of TNF-a production
from primary monocytes [69].
In murine models of C. neoformans infection, IgG3 is the pre-
dominant isotype produced during infection but antibodies of this
isotype decreased survival whereas isotype switching to IgG1
conferred protection [70]. The host-pathogen interactions of other
intracellular organisms demonstrate similar ﬁndings [71]. Anti-
bodies against the surface of Histoplasma capsulatum are protective
in mouse models but these proteins are not strongly immunogenic
as evidenced by the ﬁnding that passive transfer of immune serum
has no effect in models of lethal histoplasmosis [72]. It is plausible
then that large amounts of non-functional or even pro-
inﬂammatory antibodies are produced in the progression of
active TB disease, but that this response can be altered by
vaccination.
1.4. Potential mechanisms of AMI in TB
1.4.1. Experimental models
Passive transfer of serum studies in mouse models have been
used to broadly assess the effects of anti-mycobacterial antibodies,
and results both supportive and non-supportive of a protective role
have been recorded [13]. Experiments seeking to demonstrate the
necessity of B-cells in TB have shown conﬂicting results and have
been comprehensively reviewed elsewhere [73]. B-cells may well
play a role in granuloma formation and amelioration of inﬂam-
matory pathology, but these effects must be isolated from those
occurring as a consequence of the action of antibody.
1.4.1.1. Evidence against the role of antibodies in immunity. In mice
with normal B-cell counts but unable to secrete immunoglobulin
due to a germline AID mutation, an increased burden of bacilli was
observed in the lung and spleen upon mycobacterial challenge [74].
This bacterial burden was not abrogated by the infusion of serum
from control mice naive to mycobacterial exposure. Thus the pro-
tective effect was concluded to bemediated by cytokines such IL-10
secreted by B-cells, rather than antibodies [74]. In the same study,
uMT mice lacking both B-cells and immunoglobulin were not more
susceptible to infection than wild-type mice. However, a limitation
of this study is its inability to disprove a role for speciﬁc antibodiesagainstM.tb, as serum from non-immunized healthymice was used
to replete antibodies in the AID mutation mice [74].
1.4.1.2. Evidence in favor of a role for antibodies in immunity.
In contrast to these ﬁndings, Kozakiewicz et al. [75] found that B-
cell deﬁcient mice responded with neutrophilia after high dose
inoculation with H37Rv, and that this neutrophilia could be
reversed by administration of sera from infected C57BL/6 wild-type
mice. High infectious doses are a cause of neutrophilia, a marker of
immunopathology, and thus the abrogation of this response by
immune sera demonstrates that antibodies speciﬁc to M.tb do
contribute to protection.
Severe combined immunodeﬁciency mouse model (SCID) mice
are highly susceptible to infection with M.tb [76], In M.tb infected
mice with partially treated infection, infusion of serum from
immunized mice reduces bacillary load 100-fold and pulmonary
inﬁltration by 3-fold [76]. Given the lack of T-cells in thesemice, the
mechanism of protection here is likely the role of antibody in im-
mune serum [76]. These studies suggest a role for only anti-
mycobacterial antibody containing serum in protection against TB
independent of a B-cell mediated effect. Immune serum appears to
mediate different effects compared to serum from non-immunized
mice, most likely due to higher titres of antibodies against myco-
bacterial antigens.
1.4.2. Antibodies modulate M.tb and macrophage interaction and
enhance CMI via FcR-mediated phagocytosis (Figure 1)
Antibodies are now also understood to augment CMI and reduce
survival of intracellular pathogens via effector functions of the Fcg
receptor (FcR) (Figure 1) [77]. As previously established, CMI is
necessary for the containment of M.tb in latent infection [6]. FcR-
mediated phagocytosis of antigen concentrates antigen, improves
phagolysosomal fusion and enhances peptide presentation to T-
cells via MHC-II molecules [19]. FcR engagement is critical to the
control of other intracellular pathogens such as chlamydia, and
therefore presents a potential pathway whereby antibodies inﬂu-
ence immunity against M.tb [78].
In one of the original studies investigating the effects of opso-
nisation on uptake of M.tb, Hart et al. [79] demonstrated in 1975
that immunized rabbit serum enhanced phagolysosomal fusion in
M.tb infection by comparing the fate of opsonized and non-
opsonized phagocytosed bacteria in phagocytes using electron
microscopy (EM). Although greater phagolysosomal fusion did not
have an effect on viable intracellular bacterial numbers, this process
was still thought to beneﬁt immunity. This ﬁnding of enhanced
phagolysosomal been replicated in more recent studies [80,81].
Serum from individuals who received two booster vaccinations
with BCG showed high titres of anti-LAM antibodies and was used
to pre-treat bacilli prior tomonocyte or neutrophil uptake [81]. This
serum, but not control serum from non-vaccinated individuals
enhanced uptake and restricted growth of ingested BCG [81]. Pre-
coating of bacilli with this serum rich in anti-LAM antibodies also
led to a signiﬁcant increase in proliferating and IFN-g-expressing
CD4þ and CD8þ T cells [81].
Opsonizing antibodies isolated from healthy donors in India
were able to restrict the growth ofM.tb h37Rv in macrophages, and
showed enhancement of TNF-a and IL-12 secretion [80]. These
antibodies, but not non-opsonizing antibodies, were able to
enhance intracellular killing by increasing LAMP-1 and iNOS
localization to the phagosome as well as phagolysosome acidiﬁca-
tion [80]. FcgR/- mice are more susceptible to infection with M.tb,
and loss of function of the inhibitory FcgRIIb improves TB outcome
by enhancing IL-12, granuloma formation and IFN-g levels [82]. A
small pilot study in Ethiopia found the presence of FcgR3b copy-
number variations to confer additional risk of developing TB in
Figure 1. Antibodies modulate M.tb-macrophage interaction via FcR-mediated phagocytosis.
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evident in another Moroccan cohort [83,84].
The protective effect of IVIG in TB murine models is dependent
on antibody binding to FcR [85]. Removal of Fc region glycosylation
nulliﬁes antibody interaction with FcR and abolishes the ability of
human IVIG infusion inmice to enhance granuloma formation, lung
inﬂammation and bacillary load in infection with M.tb [85]. Anti-
body opsonization of bacilli for targeted FcR-mediated phagocy-
tosis thus appears to be a major mechanism of protection inmodels
of TB infection.
1.4.3. Other mechanisms of AMI in TB
Although FcR-mediated phagocytosis is likely to be the pre-
dominant mechanism of AMI against intracellular pathogens, other
pathways for antibody protection have been explored in TB.
Complement-induced killing by activation of membrane attack
complexes is augmented by antibody opsonisation. Complement
and IgG binding of live M.tb h37Rv increases the number of viable
intracellular bacilli, rather than reduce bacterial load which would
be expected if antibody-dependant complement-mediated
destruction occurred in TB [86]. This is in keeping with the previ-
ously mentioned activation of C1q that could be enhancing uptake
of bacilli into their intracellular niche [20].
Antibody dependant cell-mediated cytotoxicity has not yet been
described to exist through the action of antibodies against M.tb.
Antibodies are able to directly neutralize a broad range of bacterial
and viral pathogens, but little evidence exists for this action of
antibody against mycobacteria. However, yeast killer toxinelike
antibodies are able to directly bind to and kill a multi-drug resistant
strain of M.tb [87]. These antibodies were stimulated either by
natural candida infection, or by anti-idiotype inoculation of mice
with subsequent hybridoma formation [87]. More antibodies with
direct mycobactericidal properties have been described, and thus itseems unlikely that the human immune response produces
potently neutralizing antibodies capable of killing or inhibiting the
growth of mycobacteria independently of phagocytes.
1.4.4. Mucosal protection against TB
Another potential role for antibodies against TB could be to
modify the initial encounter with pathogen in the mucosal lining.
Mice lacking the polymeric Ig receptor which transports IgA into
the respiratory mucosa, are more susceptible toM.tb infection than
wild-type mice [88]. This effect is believed to be mediated by im-
mune exclusion and appears similar to ﬁndings in Salmonella
typhimurium infection where this same pIgR knockout increases
susceptibility to infection [89]. Secreted IgA is able to prevent lung
infection with intranasally inoculated Shigella ﬂexneri, a facultative
intracellular pathogen, by immune exclusion and removal of bac-
teria by mucociliary transport [90].
In an experiment demonstrating both the notion that antibodies
may prevent cell adhesion of mycobacteria and that speciﬁcity is
key to this process, Choudhary et al. [91] established that mono-
clonal and polyclonal antibodies directed only against surface an-
tigens ofMycobacterium lepraewere able to inhibit cell adhesion to
Schwann cells. Thus entry of mycobacteria into host cells may be
prevented by the action of antibody. Humans produce high titres of
IgM against mycobacterial heparin-binding hemagglutinin (HBHA),
a surface expressed molecule that facilitates host cell invasion
[92,93]. Sera from such patients were able to prevent the entry of
M.tb into an alveolar epithelial cell line [92].
In a BCG model, both IgA knock-out mice and wild-type mice
were immunized with aerosolized mycobacterium surface antigen
PstS-1 [94]. Mice unable to produce IgA were still able to produce
antigen-speciﬁc IgG and IgM, but had higher CFU numbers in the
lungs at 4 weeks post-infection. The IgA/- mice also had decreased
TNF-a and IFN-g production [94]. The role of IgA against
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solized Francisella tularensis live vaccine strain in IgA/- mice
demonstrates similar ﬁndings to those in M.tb with attenuated
markers of CMI and worse outcome [95].
In a novel experiment, polyclonal human secretory IgA (hsIgA)
was puriﬁed from colostrum donated by healthy women, and
shown to contain IgA able to bind whole BCG and M.tb lysate [96].
Prophylactic intratracheal incubation or pre-incubation of M.tb
with this hsIgA reduced bacillary load and improved granuloma
formation in the lungs of mice challenged with live M.tb [96]. This
showed that antibody capable of interacting with M.tb in the
mucosa may be passively passed on between mother and child,
and that human M.tb speciﬁc hsIgA can modify the course of
infection [96].
1.5. Monoclonal antibodies against TB
The study of monoclonal antibodies (mAbs) has been useful in
further dissecting the role of humoral immunity. The ﬁrst mAbs
against mycobacteria were described in the 1980s where hybrid-
omas were used to generate antibodies against M.tb H37Rv,
Mycobacterium bovis BCG and M. leprae [97]. It was observed that
certain mAbs bound to species-speciﬁc epitopes [97]. Giving
credence to the theory that antibodies can opsonize mycobacteria,
Glatman-Freedman et al. isolated 3 mAbs from mouse hybridomas
that were able to bind epitopes on the surface ofM.tb as conﬁrmed
by EM [98].
These mAbs were subsequently tested in a mouse model of
infection, where only the 9d8 antibody, an IgG3 speciﬁc for arabi-
nomannan, was able to prolong survival after lethal dose challenge
via enhancement of granuloma formation and iNOS localization to
cells containingM.tb [99]. Of note is that the other two mAbs, both
of the IgM isotope, were not able to enhance survival despite their
validated surface binding, conﬁrming that antibody class likely
plays a role in conferring protection [99]. The 9d8 mAb was then
tested in IFN-g and MHC class II knock-out mice, where it was less
efﬁcacious at improving protection, suggesting interaction with
CMI is required to confer protection [99]. A mAb able to bind the
AM moiety of LAM on the surface of M.tb (SMITB14) led to
improved weight loss, bacillary load and survival in M.tb challenge
when given IV prior to infection as well as when bound to bacilli
upon inoculation [100].
HBHA facilitates entry ofM.tb into epithelial cells and is required
by the bacteria to disseminate in mouse models of infection [101].
Pre-coating of BCG with anti-HBHA mAbs prior to intranasal inoc-
ulation did not inﬂuence bacterial CFU in lungs, but led to a marked
reduction in spleen colonization [101]. This ﬁnding supports pre-
viously described studies suggesting that antibodies directed
against LAM prevented dissemination of infection and that anti-
HBHA IgM is able to prevent epithelial cell invasion [92,102].
However Parra et al. [103] could not replicate the protective effects
of an anti-HBHA mAb against disseminated disease in a virulent
strain of M.tb contrary to previous ﬁndings with BCG.
1.5.1. IgA mAbs in passive immunotherapy
Other mAbs have been used in attempts to assess the possibility
that IgA in the airway protects against TB as suggested by studies
with mice lacking pIgR or the transfer of hsIgA above [89,95].
Several studies have conﬁrmed the plausibility that IgA directed
against Acr may confer passive protection [104e106]. Lopez and
Williams et al. [105,106] have shown that intratracheal or intra-
nasal inoculation with murine IgA against Acr reduces bacillary
load and improves granuloma formation. This reduction in CFU
occurred early in intra-tracheal inoculation and after 3 weeks post
intranasal administration [105,106]. Both groups compared thefunctional IgA antibody to antibodies against the 38 kDa antigen,
and antibodies of the latter speciﬁcity were found to be non-
functional, again showing that antibodies against M.tb vary in
protective function according to epitope [103,104].
Later, a single chain variable antibody fragment speciﬁc for Acr
was generated using a phage display library and then expressed in
CHO cells with a human IgA1 constant region [104]. This antibody
was tested in mice expressing a transgenic CD89 where it
demonstrated the same type of complex in vivo action observed for
the 9d8 antibody, where the therapeutic effect is greater in vivo
than in vitro. The chimeric IgA antibodywas able to reduce bacterial
load when co-administered with IFN-g, and only in the presence of
the transgenic CD89 receptor, suggesting a receptor-mediated ef-
fect with interaction with IFN-g stimulation pathways [104].
Another surface-binding murine mAb against MPT51 is able to
agglutinate cultures of the pathogenic strain CDC1551 at a con-
centration of 100ug/ml in comparison to a control anti-M.tb mAb
that did not bind the surface of this strain [107]. This corroborates
ﬁndings that antibodies can interact with inhaled mycobacteria in
the mucosa, and may be a mechanism whereby antibodies prevent
entry into host cells.
Although these studies have limitations in methodology, they
form a coherent picture (summarized in Table 2) that antibodies
contributing to immunity against M.tb are likely those that
opsonize the bacillus and are able to modulate the host macro-
phage response via targeting bacilli to FcRemediated phagocytosis.
In addition, immune exclusion may be a potential mechanism
whereby antibodies could prevent binding of mycobacterial adhe-
sins such as HBHA to host cells or cause mycobacterial clumping.
This may limit dissemination of infection or prevent entry of M.tb
into cells in the lung mucosa.
1.6. Future directions for antibody research in TB
1.6.1. Passive immunotherapy
Interest in immunotherapies against M.tb has been galvanized
by the increasing rates of drug resistance and HIV co-infection
globally [108]. Therapeutic mAbs have been proposed as one po-
tential avenue of exploration to intervene in these clinical sce-
narios, given the demonstration that several mouse mAbs improve
outcome in experimental models of disease [109].
MAbs against the surface of Methicillin Resistant Staphylo-
coccus Aureus (MRSA) have very recently been used to deliver
antibiotic directly to host cells, where MRSA appears to establish
intracellular reservoirs to evade host immunity [110]. Using similar
novel antibody-antibiotic conjugate technology, mAbs could
potentially be adapted to deliver drugs directly to TB-infected host
cells.
1.6.2. Cell-mediated immunity may not be sufﬁcient to confer
protection by vaccination
Recent studies have cast doubt on the sufﬁciency of MHC-II
restricted CD4þ cells to confer protection by vaccination. BCG-
speciﬁc CD4þ, CD8þ and gd T-cell expression of IFN-g, TNF-a, IL-2,
and IL-17 do not seem to correlate with the protection conferred
by BCG in infants [111]. However in a more recent study, BCG-
speciﬁc ELISPOT responses are associated with a reduced risk of
disease in BCG-vaccinated South African infants [37]. BCG-speciﬁc
T-cell ELISPOT antigen speciﬁc CD4þ T-cells do not appear to
localize to the site of infection in lung tissue until 18e20 days after
the establishment of disease, showing thatM.tb delays the onset of
adaptive Th1 immunity [112]. In contrast, several mAb studies
demonstrate an early impact on CFU in in vitromodels. Other arms
of the immune system such as T-cells of the gd, CD1-restricted,
Th17 and mucosal associated innate T-cells subsets have a
Table 2
Evidence suggestive of a role of antibody-mediated immunity in prevention of infection or limiting severity of disease.
Prevention of infection Limiting severity of disease Mucosal immunity
Clinical observation  High titres of IgG against PPD seen in
persistently exposed but TST- negative
individuals [45]
 Strong antibody responses against M.tb
surface in healthy controls from high
burden country [47]
 Lack of antibodies against LAM, membrane
vesicles and 38-kDa antigen associated with
risk of extra-pulmonary disease [34,36,44]
 Higher titres of IgG against Ag85A associated
with reduced risk of disease in infants [37]
 IgA against HrpA associated with
improved severity markers on
presentation in active TB disease [40]
 Oral vaccination with BCG is able to
induce anti-LAM sIgA in respiratory mu-
cosa [134]
Experimental models  No studies available to demonstrate that
antibodies prevent acquisition of
infection with M.tb
 Serum enriched for antibodies against LAM
enhances intracellular killing of M.tb [81]
 IVIG improves granuloma organization and
decreases lung CFU in mouse models [85]
 IgAKO and pIgRKO mice more susceptible
to M.tb [88,94]
 Prophylactic intra-tracheal human
secretory IgA from colostrum can protect
mice against M.tb challenge [96]
Monoclonal antibodies  MAb against MPT51 agglutinates cultures
of M.tb CDC1551 and may show immune
exclusion mechanism [107]
 Intravenous Anti-LAM mAb enhances granu-
loma formation and prolongs survival in mice
[100]
 Anti-HBHA mAb limits dissemination of BCG
in mice [103]
 Passive immunotherapy with IgA mAb
against Acr of protective beneﬁt in
mouse model [104]
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these limitations [6]. However, no prior vaccine has attempted the
induction of such a memory T-cell response.
Thus exploring whether AMI may boost vaccine-induced im-
munity offers several conceptual advantages to future vaccination
design. Firstly, antibodies have the potential to engage with the
initial inoculum of bacilli in the mucosal surface, and can thus
potentially inﬂuence host immunity earlier than CD4þ T-cell re-
sponses. Secondly, this offers a clearer path tomeasuring, at least in
part, one correlate of protection if protective mAbs can be found.
Thirdly, this approach ﬁts with current models of immunology
where antibody and CMI are synergists in conferring protection
against intracellular pathogens. A consistent ﬁnding of the pro-
tective antibodies detailed is an enhancement of cytokine pro-
duction (TNF- a, IL-12), activation of T-cells and granuloma
formation in in vivo models. This suggests that a vaccine incorpo-
rating the induction of protective antibodies may also augment the
development of an early and effective T-cell response against M.tb
1.6.3. Models of vaccines that incorporate the induction of
antibodies in TB
Such vaccines that induce both antibody and cellular responses
have been examined in animal models. Membrane vesicles from
H37Rv induce antibodies presumably to surface lipoproteins, as
well as poly-functional CD4þ cells, and are able to elicit protection
superior to live BCG in a mouse model [113]. Arabinomannan-
protein conjugate vaccination in mice induced both antibody and
T-cell responses, and the protective effect was thought to be in part
be due to antibodies that function similarly to the 9d8 antibody
described above [114]. Counteraction of LAM-induced T-cell sup-
pression and inhibition of macrophage function by antibody is
another potential mechanism for this ﬁnding [114]. Aerosolized
BCG vaccination induces an IgG as well as CMI in rhesus macaques
and improves the protection provided by intradermal BCG injection
[115]. In humans, orally administered BCG is able to induce the
formation of anti-LAM secreted IgA in the respiratory mucosa,
however the efﬁcacy of this approach has yet to be determined
[116].
Antibody speciﬁcity may be key to these observed effects, as no
protective role for B-cells was found in mice vaccinated with
aerosolized Adhu5Ag85A, the same antigen as the MVA85Avaccine
[117]. Of note is that aerosolized vaccination induced CD4þ and
CD8þ responses as well as IgG and IgA in the BAL ﬂuid against
Ag85A [117]. Rather than hinder further testing of vaccines to
induce both AMI and T-cell responses, such a study highlights theneed to identify the epitopes that are likely to stimulate functional
antibodies against M.tb. It is encouraging for vaccine design that
mucosal vaccination can induce antibody responses both systemi-
cally and in the lung mucosa, and the induction of antibodies
capable of opsonizing M.tb by aerosolized vaccination merits
testing in similar models.
1.6.4. Potential directions for future antibody research in TB
The lack of data concerning the epitopes of functional antibodies
must be addressed in order to test the contribution of such anti-
bodies to vaccine-induced immunity. Advances in the methods of
mAb production have recently led to the ability to rapidly clone
large libraries of mAbs directly from patient-derived plasmablasts
or memory B-cells [118,119]. Future work might therefore include
the production of human mAbs (hmAbs) against M.tb. Proof of this
concept is the discovery of protective hmAbs against a diverse
range of pathogens including malaria, pneumococcus, inﬂuenza
and HIV [118,120e122]. A novel envelope dimer epitope of dengue
virus was identiﬁed by characterizing hmAbs from infected pa-
tients, and this antigen appears promising for downstream vaccine
translation Further, the 3BNC117 and VRC01 hmAbs, cloned from
patients infected with HIV, have recently seen use as intravenous
therapeutics capable of reducing viral load in HIV-1 infected pa-
tients [123,124]. HmAb cloning therefore present a potent new tool
that may aide the discovery of protective antibodies against M.tb
from humans, and point to novel antigens to induce such anti-
bodies by vaccination.
Next-generation sequencing has also contributed to the eluci-
dation of the antibody repertoire in response to infection and
vaccination [125,126]. These advances may allow mapping of how
the antibody response develops during active TB infection, and
how it is subverted by M.tb to prevent the formation of any pro-
tective antibodies as suggested by the antigenic variation in B-cell
epitopes and the lack of surface-binding antibodies. The study of
clinical populations who appear to be resistant to acquiring latent
infection withM.tb are also of great interest in order to understand
immunity against TB [37]. There is strong suggestion that healthy
individuals produce high titres of antibodies to PPD and Ag85A
upon exposure to mycobacteria, and studies to assess the effect of
antibody responses on preventing active or latent infection are a
promising avenue of exploration. Ultimately, there is a need to
better understand the role for antibodies in human immunity such
that the ability of antibodies to limit dissemination of M.tb and
target bacilli for FcR-mediated phagocytosis can be harnessed by
vaccination.
A.J. Jacobs et al. / Tuberculosis 101 (2016) 102e1131102. Conclusion
Infection and disease caused by M.tb strongly stimulates hu-
moral immunity in humans. Although CMI remains the predomi-
nant correlate of protection, there is evidence to suggest that
antibodies may contribute, at least in part, to immunity. The pres-
ence of antibodies against speciﬁc M.tb antigens such as LAM ap-
pears to differ in patients with pulmonary and disseminated TB.
This corresponds to mAbs against LAM and HBHA that are able to
decrease bacillary load and prevent dissemination of mycobacterial
infection. Antibodies are now widely understood to modulate CMI
through FcR binding, and particularly surface-binding antibodies in
cases of mycobacterial infection in experimental models. It is thus
of interest that such antibodies do not seem to be stimulated during
natural infection, and the trend in protective mAbs thus far is a
suggestion that surface binding with targeting to FcR for
enhancement of CMI can occur in vivo.
These ﬁndings point to the need for further testing of whether
antibodies may confer superior protection in vaccination by
enhancing CMI, or are able to prevent infection if present prior to
host encounter withM.tb. Many challenges stand in this path, such
as a lack of knowledge concerning the existence of functional mAbs
in humans and which epitopes are likely to induce their formation.
However, new technologies now exist to conclusively address the
feasibility of incorporating goals to target AMI in the design of next-
generation vaccine candidates.
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